跳到正文

AACR 2026 年会

2026 年 4 月 17–22 日 · San Diego · 共 2429 条

← 肺癌 — 围手术期 IO、KRAS NSCLC

#SCLC

临床试验

4 人 · 5 条 · 8 篇摘要

本事件热度走势

当前热度 1·可比范围峰值 1(4月22日 01:00)·近 24 小时可比范围变化 –·当前参与者 2

参与者计数2
00.511.52
热度走势
00.511.54月21日05:004月21日12:004月21日20:004月22日03:00

上图是参与者计数,下图是热度。趋势仅比较持续完整观测到的相同主体,范围可能小于当前热度统计。移动指针或点击图表查看每小时读数;键盘可用左右方向键切换。

其他对照
证据
4618
TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

读摘要原文 →
Perioperative adebrelimab (A) plus chemotherapy (chemo) in resectable stage II-III NSCLC: Phase 3 EFS interim analysis (IA) and molecular residual disease (MRD) analysis

Yi-Long Wu, Wen-Zhao Zhong, Li-Xu Yan, Keneng Chen, Wanpu Yan, Yongzhong Luo, Wenxiang Wang, Wenqun Xing, Xiaolong Yan, Lin Wu, Feng Yao, Dongsheng Yue, Naiquan Mao, Yu Qi, Bentong Yu, Jianji Guo, Jindan Kai, Yuejun Chen, Hui Wang, Qin Zhang, Lunxu Liu, Honghai Wang, Yuanyuan Ji, Yongtao Han, Yongxiang Song, Jianjun Xu, Wei Guo, Hongxu Liu, Di Ge, Hecheng Li, XiuJuan Qu, Jifang Yao, Junfeng Liu, Tingyan Zhong, Yanhua Huang, Li Song, Wei Shi

读摘要原文 →
CT140
Final Results from S2302—PRAGMATICA-LUNG: A prospective randomized study of ramucirumab plus pembrolizumab (RP) versus standard of care (SOC) for participants (pts) previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC)

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Maya Khalil, Brian S. Henick, James Moon, Pasarlai Ahmadzai, Michael LeBlanc, Daniel R. Carrizosa, Paul J. Hesketh, Ellen V. Sigal, Jeff Allen, Andreas N. Saltos, Bryan A. Faller, Roy S. Herbst, Charles D. Blanke, Jhanelle E. Gray

读摘要原文 →
Zidesamtinib in patients with ROS1+ NSCLC previously treated with repotrectinib or taletrectinib

Geoffrey Liu, Alexander E. Drilon, Benjamin Besse, Gianluca Spitaleri, Jessica J. Lin, Byoung Chul Cho, Tatsuya Yoshida, Daniel Haggstrom, Steven Kao, Aurelie Swalduz, Misako Nagasaka, Benjamin J. Solomon, Lorenza Landi, Chiara Bennati, Elvire Pons-Tostivint, Christophe Dooms, A. J. van der Wekken, Saiama Waqar, Shirish Gadgeel, Chia-Chi Lin, Tetsuro Kondo, Hidetoshi Hayashi, Daniel Tan, Giulia Pasello, Matteo Duca, Luis G. Paz-Ares, Antonio Calles, Enriqueta Felip, Julien Mazieres, Adrianus Johannes de Langen, Alice T. Shaw, Jonathan W. Riess, Marina Garassino, Elaine Shum, Christina S. Baik, Jessica R. Bauman, D. Ross Camidge, Chien-Chung Lin, Gee-Chen Chang, Dong-Wan Kim, Myung-Ju Ahn, Ji-Youn Han, Kiichiro Ninomiya, Ryo Ariyasu, Ross Andrew Soo, Sanjay Popat, Jürgen Wolf, Maria Rosario García Campelo, Vivek A. Upadhyay, Stephen V. Liu

读摘要原文 →
现场
4月22日周三
4月21日周二
CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org